{"pageContent": "Introduction: The optimal management of prostate cancer patients presenting with prostate specific antigen (PSA) levels greater than 50 ng/ml is controversial. The purpose of this study was to investigate factors associated with overall survival and biochemical outcome in a high-risk prostate cancer population with PSA>50.0 ng/ml at time of diagnosis, and no clinical or radiological evidence of metastatic disease.", "metaData": {"source": "Prostate cancer: Towards effective combination of ADT and immunotherapy\nhttps://pubmed.ncbi.nlm.nih.gov/27112389/"}}